Journal article

Galectin-3, GDF-15, and sST2 for the assessment of disease severity and therapy response in patients suffering from inoperable chronic thromboembolic pulmonary hypertension


Authors listKriechbaum, Steffen D.; Wiedenroth, Christoph B.; Peters, Karina; Barde, Marta A.; Ajnwojner, Ruth; Wolter, Jan-Sebastian; Haas, Moritz; Roller, Fritz C.; Guth, Stefan; Rieth, Andreas J.; Rolf, Andreas; Hamm, Christian W.; Mayer, Eckhard; Keller, Till; Liebetrau, Christoph

Publication year2020

Pages578-586

JournalBiomarkers

Volume number25

Issue number7

ISSN1354-750X

eISSN1366-5804

DOI Linkhttps://doi.org/10.1080/1354750X.2020.1821776

PublisherTaylor and Francis Group


Abstract
Purpose This study examined sST2, GDF-15, and galectin-3 as indicators of disease severity and therapy response in chronic thromboembolic pulmonary hypertension (CTEPH). Methods This study included 57 inoperable CTEPH patients who underwent balloon pulmonary angioplasty and 25 controls without cardiovascular disease. Biomarker levels were examined in relation to advanced hemodynamic impairment [tertile with worst right atrial pressure (RAP) and cardiac index], hemodynamic therapy response [normalized hemodynamics (meanPAP <= 25 mmHg, PVR <= 3 WU and RAP <= 6 mmHg) or a reduction of meanPAP >= 25%; PVR >= 35%, RAP >= 25%]. Results GDF-15 [820 (556-1315) pg/ml vs. 370 (314-516) pg/ml;p < 0.001] and sST2 [53.7 (45.3-74.1) ng/ml vs. 48.7 (35.5-57.0) ng/ml; p = 0.02] were higher in CTEPH patients than in controls. At baseline, a GDF-15 level >= 1443 pg/ml (AUC 0.88; OR 31.4) and a sST2 level >= 65 ng/ml (AUC 0.80; OR 10.9) were associated with advanced hemodynamic impairment. At follow-up GDF-15 <= 958 pg/ml (AUC = 0.74, OR 18) identified patients with optimal hemodynamic therapy response and <= 760 pg/ml (AUC = 0.79, OR 14). Conclusion GDF-15 and sST2 levels are higher in CTEPH and identified patients with advanced hemodynamic impairment. Further, decreased GDF-15 levels at follow-up were associated with hemodynamic therapy response. The diagnostic strength was not superior to NT-proBNP.


Citation Styles

Harvard Citation styleKriechbaum, S., Wiedenroth, C., Peters, K., Barde, M., Ajnwojner, R., Wolter, J., et al. (2020) Galectin-3, GDF-15, and sST2 for the assessment of disease severity and therapy response in patients suffering from inoperable chronic thromboembolic pulmonary hypertension, Biomarkers, 25(7), pp. 578-586. https://doi.org/10.1080/1354750X.2020.1821776

APA Citation styleKriechbaum, S., Wiedenroth, C., Peters, K., Barde, M., Ajnwojner, R., Wolter, J., Haas, M., Roller, F., Guth, S., Rieth, A., Rolf, A., Hamm, C., Mayer, E., Keller, T., & Liebetrau, C. (2020). Galectin-3, GDF-15, and sST2 for the assessment of disease severity and therapy response in patients suffering from inoperable chronic thromboembolic pulmonary hypertension. Biomarkers. 25(7), 578-586. https://doi.org/10.1080/1354750X.2020.1821776



Keywords


ANGIOPLASTYCTEPHGalectin-3GDF-15GROWTH-DIFFERENTIATION FACTOR-15HEART-FAILUREHIGH-SENSITIVITY ASSAYNATRIURETIC-PEPTIDEremodellingSERUM-SOLUBLE ST2ST2

Last updated on 2025-21-05 at 18:22